Teladoc Q4 revenue $554M (+45% YoY); 2022 guidance $2.55-2.65B

Teladoc Health, Inc.

2021-FY EPS reported -$2.73 revenue$2,032,707,000

Q4 revenue $554.2M (+45% YoY); full year 2021 revenue $2.03B (+86% YoY).
Q4 net loss improved to $0.07 per share from $3.07 loss; full year net loss $2.73 per share.
Adjusted EBITDA Q4 $77.1M (+53% YoY); full year $267.8M (+111% YoY).
2022 revenue guidance $2.55-2.65B, representing 25-30% growth over 2021.
Full year cash from operations $194.0M vs ($53.5M) prior year, a positive swing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.